Discovery sheds light on new way to treat breast cancer
A new discovery into how breast cancer spreads could pave the way for a new treatment.
Researchers at the University of California San Diego found an inflammatory protein, TYK2, is involved in the process by which cells sense and respond to their physical environment, known as mechanotransduction.
Findings published in Nature Communications revealed that TYK2 acts as a critical breast cancer metastasis suppressor in response to stiffness in the extracellular matrix, the material surrounding and connecting cells. At low stiffness, TYK2 is found on the cell membrane, where it stops cancer cells from invading. At high stiffness, TYK2 is inactivated and found throughout the cell, allowing cancer cells to invade.
The study also indicated patients with certain types of non-invasive breast cancer could be at higher risk of developing invasive breast cancer when receiving TYK2 inhibitors, highlighting the need for enhanced breast cancer screening in patients treated with TYK2 inhibitors.
“This study reveals how extracellular matrix stiffness regulates breast cancer metastasis through TYK2 and provides new insights into how physical cues in the tumour microenvironment control cancer progression,” said Zhimin Hu, lead author of this study and Project Scientist at UC San Diego Moores Cancer Center.
“Our findings have significant implications for the clinical use of TYK2 inhibitors and underscore the importance of considering the mechanical microenvironment in cancer therapy,” added Jing Yang, corresponding author and Professor of Pharmacology at UC San Diego School of Medicine.
Understanding how TYK2 functions as a metastasis suppressor could now pave the way for new treatments for breast cancer.
